Drug Trial Radar · NCT07729956
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
436
Planned (sponsor's estimate)
Start
Sep 2, 2026
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- First posted
- Jul 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to compare the efficacy and safety of BL-B01D1 in combination with a PD-1 monoclonal antibody versus nab-paclitaxel in combination with a PD-1 monoclonal antibody in patients with PD-L1-positive, previously untreated, inoperable locally advanced or recurrent metastatic triple-negative breast cancer.
Conditions
- Triple-Negative Breast Cancer (TNBC)
Interventions
BL-B01D1Drug
Administration by intravenous infusion for a cycle of 3 weeks.
PD-1 monoclonal antibodyDrug
Administration by intravenous infusion for a cycle of 3 weeks.
Nab-paclitaxelDrug
Administration by intravenous infusion for a cycle of 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- BICR-assessed Progression-free Survival (PFS)Time frame: Up to approximately 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.